10x Genomics 2025 Q2 Earnings Strong Performance as Net Income Surges 191%

10x Genomics (TXG) reported fiscal 2025 Q2 earnings on August 8, 2025, showcasing a significant turnaround in profitability. The company’s results exceeded expectations, with revenue growth and a substantial shift from a net loss to a net profit. In addition, the firm provided a revenue outlook for the third quarter that reflects cautious optimism, factoring in external market dynamics.

Revenue
10x Genomics posted a 12.9% year-over-year increase in total revenue, reaching $172.91 million in 2025 Q2, compared to $153.10 million in 2024 Q2. Instrument sales contributed $14.50 million, with the Chromium and Spatial segments recording $5.73 million and $8.77 million, respectively. Consumables remained a strong revenue driver, bringing in $122.19 million. Within this category, Chromium and Spatial consumables accounted for $85.79 million and $36.40 million, respectively. Services and other revenue streams added $8.47 million, while license and royalty revenue contributed $27.75 million to the total. These figures highlight the company’s diversified business model and sustained demand across key product lines.

Earnings/Net Income
The company returned to profitability with an EPS of $0.28 in Q2 2025, reversing from a loss of $0.32 per share in Q2 2024, representing a 187.5% positive change. Net income surged to $34.54 million, a 191.1% positive swing from a net loss of $37.90 million in the same quarter of the previous year. This marked a significant turnaround, following seven consecutive years of losses in the corresponding fiscal quarter, underscoring the company’s improved financial health.

Price Action
Following the earnings release, TXG’s stock price declined by 15.18% during the latest trading day and dropped 6.04% for the week. However, it showed a modest 1.57% gain month-to-date.

Post-Earnings Price Action Review
A strategy of purchasing 10x Genomics shares immediately following the earnings report and holding for 30 days underperformed significantly, yielding a return of -63.58%. This underperformance lagged the benchmark by 111.49%, with a Sharpe ratio of -0.43, indicating a negative risk-adjusted return. The maximum drawdown of 0% suggested that the strategy had no room for loss.

CEO Commentary
Serge Saxonov, Co-founder and CEO, noted that the second quarter unfolded largely as expected, emphasizing resilience amid continued uncertainty in the funding environment. He expressed confidence in the company’s technology and platforms, highlighting disciplined execution as a key focus for the future.

Guidance
10x Genomics expects Q3 2025 revenue to range between $140 million and $144 million. The forecast includes an estimated $4.0 million in revenue from Chinese customers who accelerated purchases due to potential tariff changes. The company has not provided further guidance beyond this revenue range.

Additional News
In the week following 10x Genomics’ earnings release, notable Nigerian business and political developments included the arrest of a ritualist in Akwa Ibom State for allegedly providing charms to armed robbers and a significant €85 million transfer deal for Man United as part of broader football market movements. Additionally, Nigeria’s foreign direct investment dropped by 70% over three months, underscoring ongoing economic challenges. Political activity also intensified, with several resignations and party realignments reported, including the resignation of a former deputy governor from the PDP. These developments reflect broader trends affecting both corporate and political landscapes in Nigeria.